Case Study 16.1 — The Bragg Peak: Why Proton Therapy Spares Healthy Tissue

The Clinical Problem

In 2015, a 7-year-old boy was diagnosed with a medulloblastoma — a malignant brain tumor in the posterior fossa, nestled against the brainstem and cerebellum. Surgery removed the bulk of the tumor, but microscopic disease remained. Standard treatment required irradiating the entire craniospinal axis (brain and spinal cord) to 23.4 Gy, followed by a boost to the tumor bed to a total of 54 Gy.

The challenge: the developing brain of a child is exquisitely sensitive to radiation. Conventional photon radiotherapy (using 6 MV X-rays from a linear accelerator) would deliver the prescribed dose to the target, but the entrance dose, exit dose, and scattered radiation would also irradiate healthy brain tissue, the cochlea (risking hearing loss), the hypothalamus (risking growth hormone deficiency), and the hippocampus (risking neurocognitive decline).

This case — representative of hundreds treated annually — illustrates why the physics of how radiation deposits energy in tissue determines clinical outcomes. The Bragg peak is not an abstract curiosity of the Bethe-Bloch formula. It is the reason this child could be treated with dramatically less damage to healthy tissue.

The Physics: Photon vs. Proton Dose Distributions

Photon Depth-Dose

A beam of 6 MV X-rays (the standard for conventional radiotherapy) entering tissue exhibits:

1. Buildup region (0 to ~1.5 cm): Dose increases as forward-scattered electrons build up in the tissue. This is the skin-sparing effect — the surface dose is only about 50–70% of the maximum.

2. Maximum dose at ~1.5 cm depth ($d_{\max}$).

3. Exponential falloff: Beyond $d_{\max}$, dose decreases approximately exponentially with a half-value depth of about 14 cm in tissue. At 15 cm depth, the dose is roughly 50% of maximum; at 25 cm, roughly 25%.

4. No distal falloff: The beam continues to deposit dose until fully attenuated — there is always an exit dose (unless the patient is thick enough to attenuate the beam completely, which does not occur in practice for 6 MV photons).

Proton Depth-Dose

A monoenergetic proton beam exhibits the Bragg curve described in Section 16.2:

1. Low entrance dose: For a 150 MeV proton beam (range ~15.8 cm in water), the entrance dose is only about 30% of the Bragg peak dose.

2. Gradual increase: Dose increases slowly with depth as $-dE/dx$ rises (the $1/\beta^2$ behavior of the Bethe-Bloch formula).

3. Sharp Bragg peak: At 15.8 cm depth, the dose rises steeply to a maximum. The peak FWHM is approximately 4 mm.

4. Zero dose beyond the range: Within millimeters beyond the Bragg peak, the dose drops to essentially zero (except for a small contribution from secondary neutrons produced by nuclear reactions, amounting to <1% of the peak dose).

Quantitative Comparison

For a tumor at 10 cm depth:

The proton beam delivers approximately 60% less total energy to the patient than the photon beam for the same dose to the tumor.

The Spread-Out Bragg Peak (SOBP)

A single Bragg peak is too narrow (FWHM ~4 mm) to cover a tumor that may be 3–8 cm in extent. The solution is the spread-out Bragg peak (SOBP): the superposition of many Bragg peaks at different energies (and therefore different depths), weighted so that the combined dose is uniform across the tumor volume.

Passive scattering: A rotating wheel of variable thickness (range modulator wheel) degrades the beam energy by varying amounts, producing a superposition of Bragg peaks. Simple but wastes beam and produces secondary neutrons.

Active pencil-beam scanning: Magnets steer a narrow proton beam across the tumor volume in 3D (lateral scanning + energy modulation for depth). Each "spot" has its own energy and intensity. This produces the most conformal dose distribution and is the current state of the art (used at most modern proton therapy centers since ~2010).

The SOBP has a higher entrance dose than a single Bragg peak (because multiple peaks contribute), but the distal falloff remains sharp. The integral dose advantage over photons is reduced but still significant — typically a factor of 2 reduction.

Clinical Outcomes

For the medulloblastoma patient:

Photon plan (IMRT — Intensity-Modulated Radiation Therapy): - Mean cochlear dose: 33 Gy → high probability (>50%) of sensorineural hearing loss - Mean hypothalamic dose: 28 Gy → significant risk of growth hormone deficiency - Mean hippocampal dose: 24 Gy → risk of neurocognitive decline - Integral body dose: baseline

Proton plan (pencil-beam scanning): - Mean cochlear dose: 2 Gy → <5% probability of hearing loss - Mean hypothalamic dose: 0.3 Gy → negligible risk - Mean hippocampal dose: 12 Gy → reduced risk - Integral body dose: 40% of photon plan

These differences are not incremental — they represent qualitatively different long-term outcomes for a child expected to survive decades after treatment.

The Numbers Behind the Dose Advantage

To understand these clinical numbers quantitatively, consider the physics step by step.

Why is the entrance dose lower for protons? A 150 MeV proton at the surface has $\beta = 0.508$, giving $-dE/dx \approx 7.6\,\text{MeV/cm}$. At 14 cm depth (just before the Bragg peak), the proton has slowed to $\sim 30\,\text{MeV}$ ($\beta \approx 0.25$), and $-dE/dx \approx 35\,\text{MeV/cm}$. The ratio is $35/7.6 \approx 4.6$ — the proton deposits nearly 5 times more energy per centimeter at the Bragg peak than at the entrance. For 6 MV photons, the ratio of entrance dose to dose at 14 cm depth is inverted: the entrance receives more dose than the deep target.

How does the SOBP affect the entrance dose? Covering a 5 cm target (10–15 cm) requires proton energies from about 120 MeV (range 10 cm) to 150 MeV (range 15 cm). Each lower-energy beam adds to the entrance dose. For a flat SOBP, the entrance dose rises to about 60–70% of the target dose — still substantially below the photon entrance dose of 110–130% of the target dose. The net effect is a factor-of-two reduction in entrance dose.

The second-cancer argument. For a 7-year-old expected to live another 70+ years, the stochastic risk of radiation-induced second cancer is a primary concern. The risk scales with the integral dose to healthy tissue. With protons delivering 40–60% less integral dose, the lifetime second-cancer risk is estimated to decrease by 50% or more — a difference that, across thousands of pediatric patients, translates to hundreds of cancers prevented.

Limitations and Challenges of Proton Therapy

The physics advantage of the Bragg peak is real, but proton therapy is not without limitations:

Range uncertainty. The Bragg peak's sharp distal falloff is both an advantage and a vulnerability. If the actual range differs from the planned range by even 3–5 mm (due to CT calibration errors, anatomical changes between fractions, or density inhomogeneities such as bone-tissue interfaces), the distal edge of the high-dose region shifts. In photon therapy, a 5 mm shift produces a modest dose perturbation; in proton therapy, it can mean the difference between full dose to the tumor and zero dose.

Treatment planners address this by adding a distal margin (typically 3.5% of range + 1 mm) and avoiding beam directions where the distal edge points toward a critical structure.

Biological effectiveness. Protons at the Bragg peak have higher LET than at the entrance, and the relative biological effectiveness (RBE) — currently assumed to be a constant 1.1 — may be as high as 1.2–1.4 at the distal edge. An underestimated RBE at the distal falloff could cause unexpected toxicity to tissues immediately beyond the target. This is an active area of research.

Cost. A proton therapy facility costs \$100–\$200 million (compared to \$3–\$5 million for a photon linear accelerator). The economics drive the debate: is the clinical benefit large enough to justify the cost? For pediatric brain tumors, the consensus is yes. For common adult cancers (prostate, breast), randomized clinical trials are ongoing to determine whether the dosimetric advantage translates to measurable clinical benefit.

From Bethe-Bloch to the Clinic

The chain from fundamental physics to clinical benefit:

1. Bethe-Bloch formula → charged particles lose energy at a rate $\propto 1/v^2$, increasing as they slow down.

2. Bragg peak → energy deposition is concentrated at the end of the particle's range, with minimal dose beyond.

3. Range-energy relationship → the depth of the Bragg peak is controlled by the initial beam energy ($E \sim 70$–$230\,\text{MeV}$ for clinical protons).

4. SOBP → multiple energies produce a uniform dose across the tumor volume.

5. Clinical advantage → reduced integral dose, reduced damage to organs at risk, reduced late effects (hearing loss, cognitive decline, growth failure, second cancers).

Heavy Ions: Beyond Protons

Carbon-ion therapy, available at a handful of facilities worldwide (primarily in Japan and Germany), takes the Bragg peak advantage further. Carbon ions (${}^{12}$C, $z = 6$) have:

• A sharper Bragg peak. The stopping power scales as $z^2$, so carbon ions deposit 36 times more energy per unit path length than protons at the same velocity. The peak-to-entrance ratio can exceed 8:1 (compared to 3–5:1 for protons).
• Higher RBE at the peak. The dense ionization track of a carbon ion produces clustered DNA double-strand breaks that are more difficult for cells to repair. The RBE at the Bragg peak is $\sim 2$–$3$ (compared to 1.1 for protons), making carbon ions especially effective against radioresistant tumors.
• Nuclear fragmentation tail. Unlike protons, carbon ions undergo nuclear fragmentation reactions with target nuclei, producing lighter fragments (boron, beryllium, lithium, helium, hydrogen) that travel beyond the Bragg peak. This creates a small but non-negligible dose tail ($\sim 5$–$10\%$ of peak dose) that extends beyond the nominal range. This is a disadvantage compared to protons, which have no fragmentation tail.

The tradeoff — sharper peak and higher biological effectiveness versus fragmentation tail and higher facility cost — makes carbon ions the subject of ongoing clinical research.

Historical Note

Robert R. Wilson — the same physicist who led the Manhattan Project's cyclotron group and later founded Fermilab — first proposed proton therapy in a 1946 paper in Radiology. Wilson recognized that the Bragg peak, understood since W.H. Bragg's measurements in 1903, could be exploited therapeutically. The first patients were treated at the Berkeley Radiation Laboratory cyclotron in 1954. By 2024, over 100 proton therapy centers operate worldwide, and over 300,000 patients have been treated.

The Bragg peak — a direct consequence of the Bethe-Bloch formula that students derive in this chapter — continues to save lives.

Discussion Questions

1. Why do heavier ions (e.g., ${}^{12}$C) produce an even sharper Bragg peak than protons? What is the tradeoff (hint: nuclear fragmentation)?

2. The Bragg peak depth must be controlled to millimeter precision. What happens if the proton range is 5 mm shorter than planned (e.g., due to anatomical changes or CT-to-density calibration errors)?

3. Neutron therapy was tried before proton therapy but largely abandoned. Using the interaction physics of this chapter, explain why neutrons (which have no Bragg peak) are poor candidates for conformal therapy.

4. PET imaging can verify proton therapy dose delivery by detecting 511 keV annihilation photons from positron emitters (${}^{11}$C, ${}^{15}$O) produced by nuclear reactions along the beam path. How does this connect the photon detection physics of Section 16.3 to the charged-particle physics of Section 16.1?